Avancerad sökning
Visar resultat 1 - 5 av 16 avhandlingar som matchar ovanstående sökkriterier.
1. Mechanisms for immune escape in epithelial ovarian cancer
Sammanfattning : Tumors develop mechanisms to subvert the immune system, constituting immune escape. Epithelial ovarian cancer (EOC), the deadliest of all gynecological malignancies, uses a variety of mechanisms to undermine immune surveillance, aiding its establishment and metastatic spreading. LÄS MER
2. Immune modulation in serous epithelial ovarian cancer : focus on the role of tumor-derived exosomes
Sammanfattning : Serous epithelial ovarian cancer (EOC) is a potent suppressor of the immune defense. Here, we studied interactions between EOC and the immune system that lead to escape from tumor immune surveillance. LÄS MER
3. The role of RNA-binding motif 3 in epithelial ovarian cancer: A biomarker discovery approach
Sammanfattning : Epithelial ovarian cancer (EOC) is the most lethal of all gynaecological malignancies and there is an urgent need to develop new prognostic and treatment predictive biomarkers for a more efficient therapy. The discovery of the RNA-binding motif protein 3 (RBM3) as a putative cancer biomarker was based on its differential expression in various cancer forms in the Human Protein Atlas (HPA). LÄS MER
4. Immunohistochemical and molecular studies on ovarian cancer progression and prognosis
Sammanfattning : Epithelial ovarian cancer (EOC) is the most lethal malignancy of the female reproductive tract. Due to vague symptomatology, the majority of EOC patients are diagnosed in advanced clinical stages with poor survival rates, despite improvements in surgical techniques and the advent of targeted therapeutics. LÄS MER
5. Ovarian cancer. Biomarkers, surgical outcome and survival
Sammanfattning : Ovarian cancer is the eighth most common female cancer worldwide and the most lethal of the gynaecologic malignancies. Around 700 women are diagnosed in Sweden per year. Due to vague symptoms most of the patients are diagnosed with late-stage epithelial ovarian cancer (EOC) and prognosis is poor, with a five-year survival of 49%. LÄS MER